Dr. Avi Fischer, M.D., Divisional Vice President, MedicalAffairs, and Chief Medical Officer for Cardiac RhythmManagement (CRM) at Abbott discusses the recent FDA approval of the next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The new devices offer built-in smartphone connectivity via Bluetooth for increased patient-physician engagement and streamlined communications. The Gallant high voltage platforms connect to Abbott’s secure myMerlinPulse™ mobile app to allow for continuous remote monitoring and seamlessly integrates into people’s day-to-day lives.
Avi Fischer, M.D., is Divisional Vice President, Medical Affairs, and Chief Medical Officer for Cardiac Rhythm Management (CRM) at Abbott.Prior to joining Abbott, Dr. Fischer served on the faculty of the Mount Sinai School of Medicine as Director of Pacemaker and Defibrillator Therapy.Dr. Fischer received an M.D. from the Sackler School of Medicine, Tel Aviv University. He completed residency training in internal medicine at The Albert Einstein School of Medicine, Montefiore Medical Center and then completed a fellowship in cardiovascular diseases at the Mount Sinai School of Medicine and a fellowship in clinical cardiac electrophysiology at the Brigham and Women’sHospital, Harvard University. Dr. Fischer is a fellow of the American College of Cardiology and the Heart Rhythm Society and has been invited faculty at numerous international scientific congresses. He has trained and proctored physicians around the world on pacemaker and defibrillator lead management and extraction techniques. Dr. Fischer has authored numerous original publications, invited reviews and book chapters. Dr. Fischer is on the Board of Directors of the Westchester County affiliate of the AHA and a member of AHA’s NY State Advocacy Committee.